Tandem’s New t:slim X2 Pump Features Abbott FreeStyle Libre 3 Plus

Published: 31 Oct 2025

Author: Precedence Research

Share :

Tandem Diabetes Care, Inc., a global leader in the diabetes technology market, has formally introduced its next-generation automated insulin delivery (AID) system. The t:slim X2 insulin pump is combined with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) system in the U.S.

The new combination is a significant breakthrough in diabetes care, integrating two of the most reputable brands in insulin delivery and glucose monitoring. They provide increased precision, automation, and convenience to diabetes patients. The implementation is the culmination of months of these speculations after Tandem hinted at the integration earlier this year and the beginning of a strategic alliance between the two firms.

Its most recent t:slim X2 with Control-IQ+ software is fully compatible with the latest Abbott FreeStyle Libre 3 Plus sensor, which continuously measures glucose levels with high precision and low lag. The system works together to automatically determine insulin delivery, enabling the user to maintain ideal glucose levels and minimize hypo- and hyperglycemic episodes.

The integration helps Tandem achieve its long-term vision of designing an interoperable diabetes management ecosystem that enables patients to tailor their therapy experience according to the devices that best fit their lifestyles. This pairing is to be progressively scaled across the U.S. by 2025, following the implementation of the early access programs at the beginning of the year.

This integration gives Tandem a strong competitive advantage in the global diabetes device market. This places it squarely against competitors such as the MiniMed 780G by Medtronic and the Omnipod 5 system by Insulin. Furthermore, the fact that Tandem and Abbott remain concerned with interoperability aligns with the current FDA iCGM and ACE pump ecosystem, which aims to promote cross-company device compatibility. The introduction of t: slim X2 and Libre 3 Plus is not only a new product but also an indication of a significant step toward the vision of fully automated, intelligent diabetes care.